Angiogenesis inhibitory agent
AssigneeTakeda Chemical Industries, Ltd.
InventorsShoji Kishimoto, Takeshi Fujita, Tsuneo Kanamaru, Moses Judah Folkman, Donald Ingber
Life of this patent
Estimating the term…
Abstract
O-substituted fumagillol derivatives and its salts have an angiogenesis inhibiting activity and are useful for prophylaxis and treatment of diseases induced by abnormally stimulated neovascularization.
Claims6
A method of treating angiogenesis in a mammal, which comprises administering an effective amount of O-chloroacetylcarbamoylfumagillol or a pharmaceutically acceptable salt thereof to the mammal.
A method of treating angiogenesis in a mammal, which comprises administering an effective amount of a pharmaceutical composition comprising O-chloroacetylcarbamoyldihydrofumagillol or O-chloroacetylcarbamoyl-6'b-hydroxyfumagillol to the mammal.
A method of preventing angiogenesis in a mammal, which comprises administering an effective amount of O-chloroacetylcarbamoylfumagillol or a pharmaceutically acceptable salt thereof to the mammal.
A method of preventing angiogenesis in a mammal, which comprises administering an effective amount of O-chloroacetylcarbamoyldihydrofumagillol or a pharmaceutically acceptable salt thereof to the mammal.
A method of preventing angiogenesis in a mammal, which comprises administering an effective amount of O-chloroacetylcarbamoyl-6'b-hydroxyfumagillol or a pharmaceutically acceptable salt thereof to the mammal.
A method of preventing angiogenesis in a mammal, which comprises administering an effective amount of a pharmaceutical composition comprising O-chloroacetylcarbamoyldihydrofumagillol or O-chloroacetylcarbamoyl-6'b-hydroxyfumagillol to the mammal.
Dependencies are inferred from the claim text.